Dynavax to Present at William Blair's 45th Annual Growth Stock Conference
Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, announced its upcoming presentation at William Blair's 45th Annual Growth Stock Conference on June 3rd at 2:40 p.m. CT. The presentation will be accessible via webcast through the company's investor relations website.
Dynavax currently markets two commercial products: HEPLISAV-B® vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18 and older, and CpG 1018® adjuvant, which is used in HEPLISAV-B and various COVID-19 vaccines.
Dynavax Technologies (Nasdaq: DVAX), un'azienda biofarmaceutica in fase commerciale specializzata nello sviluppo di vaccini innovativi, ha annunciato la sua prossima presentazione alla 45ª Conferenza Annuale sulle Azioni di Crescita di William Blair il 3 giugno alle 14:40 CT. La presentazione sarà disponibile in webcast tramite il sito web per gli investitori della società.
Attualmente Dynavax commercializza due prodotti: il vaccino HEPLISAV-B®, approvato negli Stati Uniti, nell'UE e nel Regno Unito per la prevenzione dell'epatite B negli adulti di età superiore ai 18 anni, e l'adiuvante CpG 1018®, utilizzato in HEPLISAV-B e in diversi vaccini contro il COVID-19.
Dynavax Technologies (Nasdaq: DVAX), una empresa biofarmacéutica en etapa comercial centrada en el desarrollo innovador de vacunas, anunció su próxima presentación en la 45ª Conferencia Anual de Acciones de Crecimiento de William Blair el 3 de junio a las 2:40 p.m. CT. La presentación estará disponible vía webcast a través del sitio web de relaciones con inversionistas de la compañía.
Actualmente, Dynavax comercializa dos productos: la vacuna HEPLISAV-B®, aprobada en EE. UU., la UE y el Reino Unido para la prevención del virus de la hepatitis B en adultos mayores de 18 años, y el adyuvante CpG 1018®, que se usa en HEPLISAV-B y en varias vacunas contra el COVID-19.
Dynavax Technologies (나스닥: DVAX)는 혁신적인 백신 개발에 중점을 둔 상업 단계의 바이오제약 회사로, 6월 3일 오후 2시 40분(중부 표준시) 윌리엄 블레어 제45회 연례 성장주 컨퍼런스에서 발표할 예정임을 발표했습니다. 발표는 회사 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있습니다.
Dynavax는 현재 두 가지 상용 제품을 판매하고 있습니다: 성인 18세 이상을 대상으로 하는 B형 간염 예방용 HEPLISAV-B® 백신(미국, EU, 영국 승인)과 HEPLISAV-B 및 여러 COVID-19 백신에 사용되는 CpG 1018® 보조제입니다.
Dynavax Technologies (Nasdaq : DVAX), une entreprise biopharmaceutique en phase commerciale spécialisée dans le développement de vaccins innovants, a annoncé sa prochaine présentation lors de la 45e Conférence Annuelle sur les Actions de Croissance de William Blair le 3 juin à 14h40 CT. La présentation sera accessible en webcast via le site web des relations investisseurs de la société.
Dynavax commercialise actuellement deux produits : le vaccin HEPLISAV-B®, approuvé aux États-Unis, dans l'UE et au Royaume-Uni pour la prévention de l'hépatite B chez les adultes de 18 ans et plus, ainsi que l'adjuvant CpG 1018®, utilisé dans HEPLISAV-B et plusieurs vaccins contre la COVID-19.
Dynavax Technologies (Nasdaq: DVAX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase mit Fokus auf innovative Impfstoffentwicklung, gab seine bevorstehende Präsentation auf der 45. jährlichen Growth Stock Conference von William Blair am 3. Juni um 14:40 Uhr CT bekannt. Die Präsentation wird über einen Webcast auf der Investor-Relations-Website des Unternehmens zugänglich sein.
Dynavax vertreibt derzeit zwei kommerzielle Produkte: den HEPLISAV-B®-Impfstoff, der in den USA, der EU und Großbritannien zur Prävention von Hepatitis-B-Virus bei Erwachsenen ab 18 Jahren zugelassen ist, sowie den CpG 1018®-Adjuvans, das in HEPLISAV-B und verschiedenen COVID-19-Impfstoffen verwendet wird.
- None.
- None.
The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the
For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-william-blairs-45th-annual-growth-stock-conference-302467588.html
SOURCE Dynavax Technologies
FAQ
When is Dynavax (DVAX) presenting at William Blair's Growth Stock Conference?
What are Dynavax's (DVAX) main commercial products?
Where is HEPLISAV-B vaccine approved for use?
How can investors access Dynavax's (DVAX) conference presentation?
